Erudio Healtherudio.com
Drug
Vismodegib trials: what clinicians said in public
An HCP commentary report on 1 clinical trial studying vismodegib: CUPISCO. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 2 more trials with public commentary and no report yet.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| CUPISCO NCT03498521 · Hoffmann-La Roche | unfavourable cancer of unknown primary | Phase 2 | 358 | 62 | Deep | Oct 31, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| MyPathway NCT02091141 · Genentech, Inc. DeepView → | advanced solid tumors with molecular alterations | Phase 2 | Deep | View | |||
| SJMB12 NCT01878617 · St. Jude Children's Research Hospital FocusedView → | newly diagnosed medulloblastoma | Phase 2 | Focused | View | |||